Poolbeg Pharma #POLB – Presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting December 9, 2024 – Posted in: Blog, Poolbeg Pharma (POLB)

9 December 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces key insights from its poster presentation at the 66th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, San Diego, California. All doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome scores POLB 001 treatment showed statistically significant reductions in key cytokines Positive…

Poolbeg Pharma #POLB – CEO Jeremy Skillington talks to Alan Green March 4, 2024 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma CEO Jeremy Skillington talks to Alan Green, and recaps on the developments at the company since last year. These include the strategic collaboration with a Nasdaq-Listed Biopharma Co to use Poolbeg’s oral delivery technology, the expansion of Poolbeg’s IP, and the appointment t of a number of key former Amryt Pharma executives, namely David Allmond, John McEvoy and Laura Maher. Jeremy highlights the recent progress with the flagship POLB 001 and its potential in…

Poolbeg Pharma #POLB – Presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting December 9, 2024 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma #POLB – CEO Jeremy Skillington talks to Alan Green March 4, 2024 – Posted in: Blog, Poolbeg Pharma (POLB)

Address

Contact

Social

LEGAL